Literature DB >> 28458135

Inhibitors of cytochrome P450 (CYP) 1B1.

Raphaël Dutour1, Donald Poirier2.   

Abstract

Human cytochrome P450 1B1 (CYP1B1) is involved in the metabolism of various drugs. This enzyme catalyzes the hydroxylation of aryl compounds, thus generating more polar metabolites that can be easily excreted. CYP1B1 is also known for its ability to activate procarcinogens into carcinogens. For example, it can hydroxylate 17β-estradiol (E2) into 4-hydroxy-E2, which can promote tumorigenesis as a potent estrogen, or after being transformed into E2-3,4-quinone. Since elevated expression levels of CYP1B1 have been reported in various cancers, but not in normal tissues, this enzyme represents an interesting therapeutic target. This review put emphasis on different families of inhibitors, especially those reported since 2003.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anticancer agent; CYP1B1; Cytochrome; Enzyme; Inhibitor

Mesh:

Substances:

Year:  2017        PMID: 28458135     DOI: 10.1016/j.ejmech.2017.04.042

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  11 in total

Review 1.  Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes.

Authors:  Yeo-Jung Kwon; Sangyun Shin; Young-Jin Chun
Journal:  Arch Pharm Res       Date:  2021-01-23       Impact factor: 4.946

Review 2.  Myostatin: a multifunctional role in human female reproduction and fertility - a short review.

Authors:  Sijia Wang; Lanlan Fang; Luping Cong; Jacqueline Pui Wah Chung; Tin Chiu Li; David Yiu Leung Chan
Journal:  Reprod Biol Endocrinol       Date:  2022-07-02       Impact factor: 4.982

3.  Structure-Based Design and Synthesis of New Estrane-Pyridine Derivatives as Cytochrome P450 (CYP) 1B1 Inhibitors.

Authors:  Raphaël Dutour; Francisco Cortés-Benítez; Jenny Roy; Donald Poirier
Journal:  ACS Med Chem Lett       Date:  2017-10-11       Impact factor: 4.345

4.  Genome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B*07:02.

Authors:  Christos Tziotzios; Christos Petridis; Nick Dand; Chrysanthi Ainali; Jake R Saklatvala; Venu Pullabhatla; Alexandros Onoufriadis; Rashida Pramanik; David Baudry; Sang Hyuck Lee; Kristie Wood; Lu Liu; Seth Seegobin; Gregory A Michelotti; Su M Lwin; Evangelos A A Christou; Charles J Curtis; Emanuele de Rinaldis; Alka Saxena; Susan Holmes; Matthew Harries; Ioulios Palamaras; Fiona Cunningham; Gregory Parkins; Manjit Kaur; Paul Farrant; Andrew McDonagh; Andrew Messenger; Jennifer Jones; Victoria Jolliffe; Iaisha Ali; Michael Ardern-Jones; Charles Mitchell; Nigel Burrows; Ravinder Atkar; Cedric Banfield; Anton Alexandroff; Caroline Champagne; Hywel L Cooper; Sergio Vañó-Galván; Ana Maria Molina-Ruiz; Nerea Ormaechea Perez; Girish K Patel; Abby Macbeth; Melanie Page; Alyson Bryden; Megan Mowbray; Shyamal Wahie; Keith Armstrong; Nicola Cooke; Mark Goodfield; Irene Man; David de Berker; Giles Dunnill; Anita Takwale; Archana Rao; Tee-Wei Siah; Rodney Sinclair; Martin S Wade; Ncoza C Dlova; Jane Setterfield; Fiona Lewis; Kapil Bhargava; Niall Kirkpatrick; Xavier Estivill; Catherine M Stefanato; Carsten Flohr; Timothy Spector; Fiona M Watt; Catherine H Smith; Jonathan N Barker; David A Fenton; Michael A Simpson; John A McGrath
Journal:  Nat Commun       Date:  2019-03-08       Impact factor: 14.919

5.  WY-14643 Regulates CYP1B1 Expression through Peroxisome Proliferator-Activated Receptor α-Mediated Signaling in Human Breast Cancer Cells.

Authors:  Yong Pil Hwang; Seong Su Won; Sun Woo Jin; Gi Ho Lee; Thi Hoa Pham; Jae Ho Choi; Keon Wook Kang; Hye Gwang Jeong
Journal:  Int J Mol Sci       Date:  2019-11-25       Impact factor: 5.923

6.  CYP1B1 as a therapeutic target in cardio-oncology.

Authors:  Alexa N Carrera; Marianne K O Grant; Beshay N Zordoky
Journal:  Clin Sci (Lond)       Date:  2020-11-13       Impact factor: 6.124

7.  Inhibition of DNA Repair Pathways and Induction of ROS Are Potential Mechanisms of Action of the Small Molecule Inhibitor BOLD-100 in Breast Cancer.

Authors:  Suzanne Bakewell; Isabel Conde; Yassi Fallah; Mathew McCoy; Lu Jin; Ayesha N Shajahan-Haq
Journal:  Cancers (Basel)       Date:  2020-09-16       Impact factor: 6.639

Review 8.  Cytochrome P450 Enzymes and Drug Metabolism in Humans.

Authors:  Mingzhe Zhao; Jingsong Ma; Mo Li; Yingtian Zhang; Bixuan Jiang; Xianglong Zhao; Cong Huai; Lu Shen; Na Zhang; Lin He; Shengying Qin
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

Review 9.  Drug-Metabolizing Cytochrome P450 Enzymes Have Multifarious Influences on Treatment Outcomes.

Authors:  Yurong Song; Chenxi Li; Guangzhi Liu; Rui Liu; Youwen Chen; Wen Li; Zhiwen Cao; Baosheng Zhao; Cheng Lu; Yuanyan Liu
Journal:  Clin Pharmacokinet       Date:  2021-03-16       Impact factor: 6.447

Review 10.  Structure-Based Drug Design for Cytochrome P450 Family 1 Inhibitors.

Authors:  Zbigniew Dutkiewicz; Renata Mikstacka
Journal:  Bioinorg Chem Appl       Date:  2018-07-25       Impact factor: 7.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.